Prediction of Clearance, Volume of Distribution and Half-life by Allometric Scaling and by use of Plasma Concentrations Predicted from Pharmacokinetic Constants: a Comparative Study
The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
Pharmacokinetic parameters (clearance, CL, volume of distribution in the central compartment, VdC, and elimination half-life, t1/2beta) predicted by an empirical allometric approach have been compared with parameters predicted from plasma concentrations calculated by use of the pharmacokinetic constants A, B, alpha and beta, where A and B are the intercepts on the Y axis of the plot of plasma concentration against time and alpha and beta are the rate constants, both pairs of constants being for the distribution and elimination phases, respectively. The pharmacokinetic parameters of cefpiramide, actisomide, troglitazone, procaterol, moxalactam and ciprofloxacin were scaled from animal data obtained from the literature. Three methods were used to generate plots for the prediction of clearance in man: dependence of clearance on body weight (simple allometric equation); dependence of the product of clearance and maximum life-span potential (MLP) on body weight; and dependence of the product of clearance and brain weight on body weight. Plasma concentrations of the drugs were predicted in man by use of A, B, alpha and beta obtained from animal data. The predicted plasma concentrations were then used to calculate CL, VdC and t1/2beta. The pharmacokinetic parameters predicted by use of both approaches were compared with measured values. The results indicate that simple allometry did not predict clearance satisfactorily for actisomide, troglitazone, procaterol and ciprofloxacin. Use of MLP or the product of clearance and brain weight improved the prediction of clearance for these four drugs. Except for troglitazone, VdC and t1/2beta predicted for man by use of the allometric approach were comparable with measured values for the drugs studied. CL, VdC and t1/2beta predicted by use of pharmacokinetic constants were comparable with values predicted by simple allometry. Thus, if simple allometry failed to predict clearance of a drug, so did the pharmacokinetic constant approach (except for actisomide). The results of this study indicate that caution should be employed in interpreting plasma concentrations predicted for a drug in man by use of pharmacokinetic constants obtained in animals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“When the exponent exceeds 1.0, a two-term power equation incorporating CL × BrW and body weight is recommended [6,9].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [9]
In the citing paper
“Recognizing the limitations of simple allometry, various correction factors have been proposed to improve the accuracy of human clearance predictions [9,58,59,60].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [9]
Citations
Cites
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925 · cited 1×
“Many theories and different approaches have been proposed for improving the predictive performance of allometry for CL, VdC and t1=2b (Dedrick 1973; Boxenbaum 1982, 1984; Houston 1994; Mahmood & Balian 1996a, b).”
BackgroundInterspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648
Dedrick, R. L. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059667 · Cited by 397
Interspecies Pharmacokinetic Scaling and the Evolutionary-Comparative Paradigm
Boxenbaum, H. (1984) · Drug Metabolism Reviews · doi:10.3109/03602538409033558 · Cited by 267 · cited 1×
“Many theories and different approaches have been proposed for improving the predictive performance of allometry for CL, VdC and t1=2b (Dedrick 1973; Boxenbaum 1982, 1984; Houston 1994; Mahmood & Balian 1996a, b).”
BackgroundInterspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257
Self-citationInterspecies correlation of plasma concentration history of methotrexate (NSC-740).
Dedrick, R. L., Bischoff, K. B., & Zaharko, D. S. (1970) · PubMed · Cited by 241
Mahmood, I., & Balian, J. D. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js950400y · Cited by 105 · cited 4×
“The exponent of moxalactam and cefpiramide was less than 0 7, hence according to Mahmood & Balian (1996b) simple allometry should predict the clearance of these two drugs with reasonable accuracy.”
BackgroundMethodSelf-citationScaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species
Boxenbaum, H. G., & Fertig, J. B. (1984) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03189622 · Cited by 93
Pharmacokinetic Scale-up: Accurate Prediction of Human Pharmacokinetic Profiles from Animal Data
Mordenti, J. J. (1985) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600741017 · Cited by 87 · cited 3×
“In another approach Swabb & Bonner (1983) and Mordenti (1985) predicted the plasma concentrations of aztreonam and ceftizoxime, respectively, by use of allometric relationships between pharmacokinetic parameters and pharmacokinetic constants A, B, a and b, where A and B are the intercepts on the Y…”
MethodCiba Foundation Colloquia on Ageing
Wolstenholme, G. E. W. (2015) · Cited by 87
Izumi, T., Enomoto, S., Hosiyama, K., Sasahara, K., Shibukawa, A., Nakagawa, T., & Sugiyama, Y. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13117-0 · Cited by 85 · cited 1×
“The absolute bioavailability of troglitazone and procaterol were assumed to be 20% (Izumi et al 1996) and 30% (Eldon et al 1993), respectively.”
BackgroundNouws, J. F. M., Mevius, D. J., Vree, T. B., Baars, A. M., & Laurensen, J. (1988) · Veterinary Quarterly · doi:10.1080/01652176.1988.9694165 · Cited by 64
Ciba Foundation Colloquia on Aging
Montagu, A. (1964) · American Journal of Psychiatry · doi:10.1176/ajp.120.7.727-a · Cited by 60
Dose ranging study and constant infusion evaluation of ciprofloxacin
Drusano, G. L., Plaisance, K. I., Forrest, A., & Standiford, H. C. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.30.3.440 · Cited by 59
Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys
Matsui, H., Yano, K., & Okuda, T. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.22.2.213 · Cited by 42
Disposition of ciprofloxacin following intravenous administration in dogs
ABADÍA, A. R., ARAMAYONA, J. J., MUÑOZ, M. J., DELFINA, J. M. P., SAEZ, M. P., & BREGANTE, M. A. (1994) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.1994.tb00264.x · Cited by 42
Aramayona, J. J., Mora, J., Fraile, L. J., Garcia, M. A., Abadía, A. R., & Bregante, M. A. (1996) · American Journal of Veterinary Research · doi:10.2460/ajvr.1996.57.04.547 · Cited by 42
Prediction of aztreonam pharmacokinetics in humans based on data from animals
Swabb, E. A., & BONNER, D. P. (1983) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061865 · Cited by 39
Pharmacokinetics of cefpiramide (SM-1652) in humans
Nakagawa, K., Koyama, M., Matsui, H., Ikeda, C., Yano, K., Nakatsuru, N., Yoshinaga, K., & Noguchi, T. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.2.221 · Cited by 33
Pharmacokinetics of a Novel Antiarrhythmic Drug, Actisomide
Cook, C. S., Rozek, L. F., Stolzenbach, J. C., Anderson, S., Schoenhard, G. L., & Karim, A. (1993) · Pharmaceutical Research · doi:10.1023/a:1018900725050 · Cited by 21
Clinical Pharmacokinetics and Relative Bioavailability of Oral Procaterol
Eldon, M. A., Battle, M. M., Coon, M. J., Nordblom, G. D., Sedman, A. J., & Colburn, W. A. (1993) · Pharmaceutical Research · doi:10.1023/a:1018966506819 · Cited by 15
Pharmacokinetics of procaterol in the rat, rabbit and beagle dog.
Ishigami, M., Saburomaru, K., Niino, K., Kido, M., Morita, S., Miyamoto, G., & Kohri, H. (1979) · PubMed · Cited by 12
Cefroxadine (CGP-9000) にかんする臨床的研究
上田, 泰., 松本, 文., 斉藤, 篤., 嶋田, 甚., 大森, 雅., 柴, 孝., 山路, 武., 井原, 裕., 北條, 敏., & 宮原, 正. (1980) · Chemotherapy · Cited by 4
秀雄, 山., 正, 吉., 尾熊, 隆., 木村, 靖., 栩野, 義., 二郎, 栗., 松本, 慶., 良夫, 宇., 春美, 宍., & 毅, 永. (1980) · Chemotherapy · doi:10.11250/chemotherapy1953.28.supplement7_251 · Cited by 3
Research works printed but not linked: 2
- Sugeno, 1980, Disposition of 6059-S in rats, dogs and monkeys, Chemotherapy, 28, 194
- Yamada, 1980, Clinical pharmacology of 6059-S in healthy volunteers, Chemotherapy, 28, 251
Cited by
Dose adjustment of anaesthetics in the morbidly obese
Ingrande, J., & Lemmens, H. J. M. (2010) · British Journal of Anaesthesia · doi:10.1093/bja/aeq312 · Cited by 445
Metabolic Scaling in Animals: Methods, Empirical Results, and Theoretical Explanations
White, C. R., & Kearney, M. R. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c110049 · Cited by 181
“This is an often quoted use of allometry (e.g., 149, 200, 235, 246, 247, 256, 267, 268, 287, 289) and is particularly prevalent in the human literature where scaling principles have been used to predict rates of metabolism (e.g., 172, 173, 284) and drug clearance (e.g., 396, 397, 398).”
Caldwell, G. W., Masucci, J. A., Yan, Z., & Hageman, W. (2004) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190588 · Cited by 148
“V~, Varea, and Vss) from animal data has been shown to accurately predict the human volume of distribution (31).”
BackgroundMethodInfluentialA NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALING
Tang, H., & Mayersohn, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004143 · Cited by 141
Lombardo, F., Waters, N. J., Argikar, U. A., Dennehy, M. K., Zhan, J., Gunduz, M., Harriman, S. P., Berellini, G., Liric Rajlic, I., & Obach, R. S. (2013) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012440282 · Cited by 106
Metadata
- Authors
- Mahmood, I.
- Affiliations
- United States Food and Drug Administration (US)
- Corresponding author
- Mahmood, Iftekhar
- ORCID
- Mahmood, Iftekhar
- Venue
- Journal of Pharmacy and Pharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-08-01
- Volume
- 51
- Issue
- 8
- Pages
- 905-910
- ISSN
- 0022-3573 (ISSN-L)
- 2042-7158
- OpenAlex
- W1965285716
- Cited by
- 59
- References
- 25
- Citations by year
- 2026: 2 · 2024: 1 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2015: 1 · 2014: 3 · 2013: 2 · 2012: 7
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Pharmacy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- allometric scaling, clearance, volume of distribution, elimination half-life, plasma concentration prediction, brain weight, cefpiramide, troglitazone, procaterol, moxalactam, ciprofloxacin, interspecies extrapolation
- MeSH terms
- Animals, Blood Chemical Analysis, Data Collection, Humans, Life Expectancy, Models, Biological, Pharmacokinetics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.